Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -68.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -68.39% |
| Cost of Revenue | 125.35% | 84.77% | 26.38% | -4.75% | -10.20% |
| Gross Profit | -126.85% | -87.49% | -28.84% | 2.44% | 9.09% |
| SG&A Expenses | 163.78% | 113.47% | 69.02% | 5.52% | 6.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 137.63% | 94.41% | 40.48% | -1.38% | -4.66% |
| Operating Income | -138.62% | -96.30% | -42.31% | -0.21% | 3.85% |
| Income Before Tax | -125.79% | -90.35% | -44.62% | -2.27% | 3.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -125.79% | -90.35% | -44.62% | -2.27% | 3.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.79% | -90.35% | -44.62% | -2.27% | 3.40% |
| EBIT | -138.62% | -96.30% | -42.31% | -0.21% | 3.85% |
| EBITDA | -138.69% | -97.90% | -43.44% | -0.97% | 3.15% |
| EPS Basic | 61.55% | 47.30% | 33.74% | 26.00% | 29.52% |
| Normalized Basic EPS | 61.08% | 46.88% | 33.75% | 26.00% | 29.52% |
| EPS Diluted | 61.55% | 47.30% | 33.74% | 26.00% | 29.52% |
| Normalized Diluted EPS | 61.08% | 46.88% | 33.75% | 26.00% | 29.52% |
| Average Basic Shares Outstanding | 893.58% | 616.56% | 310.72% | 36.93% | 36.59% |
| Average Diluted Shares Outstanding | 893.58% | 616.56% | 310.72% | 36.93% | 36.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |